{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:05:35Z","timestamp":1791140735562,"version":"4.1.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Invasive nontyphoidal\n                      <jats:italic>Salmonella<\/jats:italic>\n                      (iNTS) disease is one of the most common causes of bacteremia in sub-Saharan Africa (sSA), mostly affecting children less than 5 years of age and with an associated 14.7% case fatality ratio. This disease is responsible for 62,018 deaths worldwide annually with more than 80% of those occurring in sSA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This work describes the pre-clinical development of a Generalized Modules for Membrane Antigens (GMMA)-based bivalent vaccine candidate against iNTS disease, known as iNTS-GMMA.\n                      <jats:italic>Salmonella enterica<\/jats:italic>\n                      serovars Typhimurium (\n                      <jats:italic>S<\/jats:italic>\n                      . Typhimurium) and Enteritidis (\n                      <jats:italic>S<\/jats:italic>\n                      . Enteritidis) were genetically modified to induce hyperblebbing of outer membrane vesicles, referred to as GMMA, with a penta-acylated lipid A of the lipopolysaccharide (LPS), characterized by a reduced induction of proinflammatory cytokine release from monocytes compared to GMMA carrying wild-type species of lipid A. GMMA derived from the genetically modified\n                      <jats:italic>Salmonella<\/jats:italic>\n                      strains were produced at scale with high yields and purity under both non-good manufacturing practice (GMP) conditions and under GMP conditions. A simple two-step filtration process was used to purify the GMMA drug substances. Subsequently, the\n                      <jats:italic>S<\/jats:italic>\n                      . Typhimurium GMMA and\n                      <jats:italic>S<\/jats:italic>\n                      . Enteritidis GMMA were individually formulated on Alhydrogel to produce the drug products. Mixing of the two components prior to injection results in the iNTS-GMMA vaccine candidate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The iNTS-GMMA vaccine candidate induced in mice and rabbits high levels of IgG anti-\n                      <jats:italic>S<\/jats:italic>\n                      . Typhimurium and\n                      <jats:italic>S<\/jats:italic>\n                      . Enteritidis LPS O-antigens, the target antigens of the vaccine. Moreover, animal sera elicited strong\n                      <jats:italic>in vitro<\/jats:italic>\n                      bactericidal activity against\n                      <jats:italic>S<\/jats:italic>\n                      . Typhimurium and\n                      <jats:italic>S<\/jats:italic>\n                      . Enteritidis strains. Additionally, the highest envisioned human dose of iNTS-GMMA was well tolerated in a GLP repeated-dose toxicology study in rabbits.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data supported clinical evaluation of this urgently needed vaccine against iNTS disease in sSA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1821495","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:57:52Z","timestamp":1780390672000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of a GMMA-based candidate vaccine against invasive nontyphoidal Salmonella disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Francesco","family":"Citiulo","sequence":"first","affiliation":[{"name":"GSK Vaccines Institute for Global Health S.r.l. (GVGH)","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Koeberling","sequence":"additional","affiliation":[{"name":"GSK Vaccines Institute for Global Health S.r.l. (GVGH)","place":["Siena, Italy"]},{"name":"VectorY Therapeutics","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Rossi","sequence":"additional","affiliation":[{"name":"GSK Vaccines Institute for Global Health S.r.l. (GVGH)","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Cappelletti","sequence":"additional","affiliation":[{"name":"GSK Vaccines Institute for Global Health S.r.l. (GVGH)","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Giannelli","sequence":"additional","affiliation":[{"name":"GSK Vaccines Institute for Global Health S.r.l. (GVGH)","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Aruta","sequence":"additional","affiliation":[{"name":"GSK Vaccines Institute for Global Health S.r.l. (GVGH)","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"De Simone","sequence":"additional","affiliation":[{"name":"GSK Vaccines Institute for Global Health S.r.l. (GVGH)","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pippi","sequence":"additional","affiliation":[{"name":"GSK Vaccines Institute for Global Health S.r.l. (GVGH)","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xhenti","family":"Ferhati","sequence":"additional","affiliation":[{"name":"GSK Vaccines Institute for Global Health S.r.l. (GVGH)","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"De Felice","sequence":"additional","affiliation":[{"name":"GSK Vaccines Institute for Global Health S.r.l. (GVGH)","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Acquaviva","sequence":"additional","affiliation":[{"name":"GSK Vaccines Institute for Global Health S.r.l. (GVGH)","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Daniele","sequence":"additional","affiliation":[{"name":"GSK Vaccines Institute for Global Health S.r.l. (GVGH)","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomena","family":"De Luca","sequence":"additional","affiliation":[{"name":"GSK Vaccines Institute for Global Health S.r.l. (GVGH)","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Iannello","sequence":"additional","affiliation":[{"name":"GSK Vaccines Institute for Global Health S.r.l. (GVGH)","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia G.","family":"Vitali","sequence":"additional","affiliation":[{"name":"GSK Vaccines","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Necchi","sequence":"additional","affiliation":[{"name":"GSK Vaccines Institute for Global Health S.r.l. (GVGH)","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura B.","family":"Martin","sequence":"additional","affiliation":[{"name":"GSK Vaccines Institute for Global Health S.r.l. (GVGH)","place":["Siena, Italy"]},{"name":"CEPI (Coalition for Epidemic Preparedness Innovations)","place":["Washington DC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Berlanda Scorza","sequence":"additional","affiliation":[{"name":"GSK Vaccines Institute for Global Health S.r.l. (GVGH)","place":["Siena, Italy"]},{"name":"GSK Vaccines","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Colucci","sequence":"additional","affiliation":[{"name":"GSK Vaccines Institute for Global Health S.r.l. (GVGH)","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Canals","sequence":"additional","affiliation":[{"name":"GSK Vaccines Institute for Global Health S.r.l. (GVGH)","place":["Siena, Italy"]},{"name":"GSK Global Health Medicines R&D","place":["Tres Cantos, Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.06.029","article-title":"Incidence of non-typhoidal Salmonella invasive disease: a systematic review and meta-analysis","volume":"83","author":"Marchello","year":"2021","journal-title":"J Infect"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(11)61752-2","article-title":"Invasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in Africa","volume":"379","author":"Feasey","year":"2012","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1097\/QCO.0b013e32834a9980","article-title":"Invasive nontyphoidal Salmonella disease: epidemiology, pathogenesis and diagnosis","volume":"24","author":"Gordon","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/s1473-3099(21)00615-0","article-title":"Complications and mortality of non-typhoidal salmonella invasive disease: a global systematic review and meta-analysis","volume":"22","author":"Marchello","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ691","article-title":"Three epidemics of invasive multidrug-resistant Salmonella bloodstream infection in Blantyre, Malawi, 1998-2014","volume":"61","author":"Feasey","year":"2015","journal-title":"Clin Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1038\/s41467-019-11844-z","article-title":"An African Salmonella Typhimurium ST313 sublineage with extensive drug-resistance and signatures of host adaptation","volume":"10","author":"Van Puyvelde","year":"2019","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ713","article-title":"Invasive Salmonella infections at multiple surveillance sites in the Democratic Republic of the Congo, 2011-2014","volume":"61","author":"Kalonji","year":"2015","journal-title":"Clin Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy898","article-title":"Multidrug-resistant nontyphoidal Salmonella hotspots as targets for vaccine use in management of infections in endemic settings","volume":"68","author":"Kariuki","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/jci33998","article-title":"The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children","volume":"118","author":"MacLennan","year":"2008","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-005659","article-title":"The genomic epidemiology of multi-drug resistant invasive non-typhoidal Salmonella in selected sub-Saharan African countries","volume":"6","author":"Park","year":"2021","journal-title":"BMJ Glob Health"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127008","article-title":"Landscape analysis of invasive non-typhoidal salmonella (iNTS) disease and iNTS vaccine use case and demand: report of a WHO expert consultation","volume":"55","author":"Emary","year":"2025","journal-title":"Vaccine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/infdis\/jiu045","article-title":"Sequential acquisition of T cells and antibodies to nontyphoidal Salmonella in Malawian children","volume":"210","author":"Nyirenda","year":"2014","journal-title":"J Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1006\/mpat.1996.0059","article-title":"Immunoprotection by monoclonal antibodies to the porins and lipopolysaccharide of Salmonella typhimurium","volume":"21","author":"Singh","year":"1996","journal-title":"Microb Pathog"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1128\/iai.05484-11","article-title":"Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis","volume":"79","author":"Simon","year":"2011","journal-title":"Infect Immun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.micpath.2013.05.014","article-title":"Invasive African Salmonella Typhimurium induces bactericidal antibodies against O-antigens","volume":"63","author":"Rondini","year":"2013","journal-title":"Microb Pathog"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134478","article-title":"Production of a Shigella sonnei vaccine based on generalized modules for membrane antigens (GMMA), 1790GAHB","volume":"10","author":"Gerke","year":"2015","journal-title":"PloS One"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1128\/cvi.00023-16","article-title":"Toll-like receptor activation by generalized modules for membrane antigens from lipid A mutants of Salmonella enterica serovars Typhimurium and Enteritidis","volume":"23","author":"Rossi","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/isrctn51750695","article-title":"Salmonella vaccine study in Oxford (SALVO) trial: protocol for an observer-participant blind randomised placebo-controlled trial of the iNTS-GMMA vaccine within a European cohort","volume":"13","author":"Hanumunthadu","year":"2023","journal-title":"BMJ Open"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.07.013","article-title":"Safety profile and immunologic responses of a novel vaccine against Shigella sonnei administered intramuscularly, intradermally and intranasally: results from two parallel randomized phase 1 clinical studies in healthy adult volunteers in Europe","volume":"22","author":"Launay","year":"2017","journal-title":"EBioMedicine"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00596-x","article-title":"GMMA technology for the development of safe vaccines: meta-analysis of individual patient data to assess the safety profile of Shigella sonnei 1790GAHB vaccine in healthy adults, with special focus on neutropenia","volume":"11","author":"De Ryck","year":"2022","journal-title":"Infect Dis Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00335","article-title":"Booster vaccination with GVGH Shigella sonnei 1790GAHB GMMA vaccine compared to single vaccination in unvaccinated healthy European adults: results from a phase 1 clinical trial","volume":"10","author":"Launay","year":"2019","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1101\/2023.06.13.23291315","article-title":"Prevalence and distribution of non-typhoidal Salmonella enterica serogroups and serovars isolated from normally sterile sites: a global systematic review","volume":"152","author":"Hagedoorn","year":"2023","journal-title":"Epidemiol Infect"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2020.101433","article-title":"Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella","volume":"115","author":"Micoli","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050495","article-title":"Long-term anti-bacterial immunity against systemic infection by Salmonella enterica serovar Typhimurium elicited by a GMMA-based vaccine","volume":"9","author":"Fiorino","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1610067","article-title":"GMMA-based vaccine candidates against invasive nontyphoidal salmonellosis elicit bactericidal antibodies against a panel of epidemiologically relevant Salmonellae","volume":"16","author":"De Simone","year":"2025","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105903","article-title":"Safety and immunogenicity of the invasive non-typhoidal Salmonella (iNTS)-GMMA vaccine: a first-in-human, randomised, dose escalation trial","volume":"119","author":"Hanumunthadu","year":"2025","journal-title":"EBioMedicine"},{"key":"B27","unstructured":"A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2023.2270596","article-title":"The iNTS-GMMA vaccine: a promising step in non-typhoidal Salmonella vaccine development","volume":"22","author":"Skidmore","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1099\/00221287-137-3-601","article-title":"Reference collection of strains of the Salmonella typhimurium complex from natural populations","volume":"137","author":"Beltran","year":"1991","journal-title":"J Gen Microbiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139847","article-title":"Strain selection for generation of O-antigen-based glycoconjugate vaccines against invasive nontyphoidal Salmonella disease","volume":"10","author":"Lanzilao","year":"2015","journal-title":"PloS One"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.11.004","article-title":"Pan-European resistance monitoring programmes encompassing food-borne bacteria and target pathogens of food-producing and companion animals","volume":"41","author":"de Jong","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"B32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41541-023-00725-8","article-title":"A next-generation GMMA-based vaccine candidate to fight shigellosis","volume":"8","author":"Rossi","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-1900-1_14","article-title":"Methods for assessment of OMV\/GMMA quality and stability","volume":"2414","author":"Micoli","year":"2022","journal-title":"Methods Mol Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2019.04.012","article-title":"Development of FAcE (Formulated Alhydrogel competitive ELISA) method for direct quantification of OAg present in Shigella sonnei GMMA-based vaccine and its optimization using Design of Experiments approach","volume":"471","author":"Necchi","year":"2019","journal-title":"J Immunol Methods"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9258(18)56740-5","article-title":"The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamine, and its analytical application","volume":"180","author":"Hestrin","year":"1949","journal-title":"J Biol Chem"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212160","article-title":"Comparison and optimization of quantification methods for Shigella flexneri serotype 6 O-antigen containing galacturonic acid and methyl-pentose","volume":"22","author":"Raso","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9030229","article-title":"Stability of outer membrane vesicles-based vaccines, identifying the most appropriate methods to detect changes in vaccine potency","volume":"9","author":"Palmieri","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9071375","article-title":"Development of a monocyte activation test as an alternative to the rabbit pyrogen test for mono- and multi-component Shigella GMMA-based vaccines","volume":"9","author":"Carson","year":"2021","journal-title":"Microorganisms"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/biotech12030054","article-title":"Characterization of enzyme-linked immunosorbent assay (ELISA) for quantification of antibodies against Salmonella Typhimurium and Salmonella Enteritidis O-antigens in human sera","volume":"12","author":"Aruta","year":"2023","journal-title":"Biotech (Basel)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172163","article-title":"Development of a high-throughput method to evaluate serum bactericidal activity using bacterial ATP measurement as survival readout","volume":"12","author":"Necchi","year":"2017","journal-title":"PloS One"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1101\/gr.091017.109","article-title":"Epidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype","volume":"19","author":"Kingsley","year":"2009","journal-title":"Genome Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2012.10.038","article-title":"A scalable method for O-antigen purification applied to various Salmonella serovars","volume":"434","author":"Micoli","year":"2013","journal-title":"Anal Biochem"},{"key":"B43","volume-title":"Pyrogens","year":"2013"},{"key":"B44","volume-title":"WHO Technical Report Series, No. 927, 2005","year":"2005"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2026.128339","article-title":"The invasive non-typhoidal Salmonella vaccine landscape: innovations and challenges ahead","volume":"76","author":"Revie","year":"2026","journal-title":"Vaccine"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.715393","article-title":"GMMA-based vaccines: the known and the unknown","volume":"12","author":"Mancini","year":"2021","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201800376","article-title":"Emerging technologies for low-cost, rapid vaccine manufacture","volume":"14","author":"Kis","year":"2019","journal-title":"Biotechnol J"},{"key":"B48","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41541-021-00281-z","article-title":"Burkholderia pseudomallei OMVs derived from infection mimicking conditions elicit similar protection to a live-attenuated vaccine","volume":"6","author":"Baker","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0910497107","article-title":"Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal Salmonella by blood cells in Africans","volume":"107","author":"Gondwe","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.12688\/wellcomeopenres.18054.2","article-title":"Understanding the epidemiology of iNTS disease in Africa in preparation for future iNTS- vaccine studies in endemic countries: Seroepidemiology in Africa of iNTS (SAiNTS) study protocol: Malawi site [version 9.0","volume":"8","author":"Dale","year":"2023","journal-title":"Wellcome Open Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.11.089","article-title":"Characterization of O-antigen delivered by Generalized Modules for Membrane Antigens (GMMA) vaccine candidates against nontyphoidal Salmonella","volume":"35","author":"De Benedetto","year":"2017","journal-title":"Vaccine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1821495\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:57:57Z","timestamp":1780390677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1821495\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2026.1821495"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1821495","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"article-number":"1821495"}}